Current Editions
Sizing up Lilly’s dealmaking spree
Megacap commits over $45B towards M&A and partnerships so far in 2026
Data Byte
Product Development
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer
Vopimetostat becomes the first to show potential additive efficacy with the pan-RAS inhibitor in PDAC
Regulation
Calmer waters for FDA; Servier, Lilly deals — a BioCentury podcast
New leaders set tone at FDA; billion-dollar deals pace biopharma BD
Deals
In its largest M&A deal, Incyte adds late-stage bleeding candidate via Vega buy
Structure of $1.25B deal funnels returns to shareholders through holding company Star; milestones could bring total value to $2B
J&J/Firefly, Roche/Nurix each strike degrader deals: Deals Report
Plus: Incyte/Vega; GSK/Engitix; Lilly/Ascidian; and more
BioCentury ISSN 1097-7201